Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

2015358 citationsJournal Article

Authors

Wilfried Eberhardt · Ruhrlandklinik

Christoph Pöttgen · Ruhrlandklinik

Thomas Gauler · Ruhrlandklinik

Godehard Friedel · Ruhrlandklinik

Stefanie Veit · Ruhrlandklinik

Vanessa Heinrich · Ruhrlandklinik

Stefan Welter · Ruhrlandklinik

Abstract

The 5-year OS and PFS rates in randomly assigned patients with resectable stage III non-small-cell lung cancer were excellent with both treatments. Both are acceptable strategies for this good-prognosis group.

Topics & Keywords

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Lung Cancer Research Studies

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 35, pp. 4194-4201

DOI: 10.1200/jco.2015.62.6812

Field-Weighted Citation Impact: 25.11